Literature DB >> 3370058

Chemistry and pharmacological properties of the pyridine-3-sulfonylurea derivative torasemide.

J Delarge1.   

Abstract

Out of a series of pyridine-3-sulfonylureas with diuretic activity torasemide (1-isopropyl-3- ([4-(3-methyl-phenylamino)pyridine]-3-sulfonyl)urea) has been proved to be one of the most active derivatives. In the rat, urinary volume and electrolyte excretions increased linearily with the logarithm of the dose, thus resembling the profile of a high ceiling diuretic. Experiments by oral and intravenous routes indicated that torasemide was equally potent both by oral and parenteral administration. Compared to furosemide, torasemide was 9-40 times more potent on weight basis in the rat. For the same natriuretic effect, however, potassium losses with torasemide were significantly less than with furosemide. The diuretic effect of torasemide lasted longer compared to that of furosemide. In accordance with the pharmacodynamic characteristics plasma elimination half-life of torasemide was about 1.5 h in the rat and bioavailability was nearly complete. Torasemide was 98-99% bound to plasma proteins. No in vitro interaction was found with the cumarine derivative warfarin.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3370058

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  5 in total

Review 1.  Effects of diuretics on outputs and flows of urine and urinary solutes in healthy subjects.

Authors:  A J Reyes
Journal:  Drugs       Date:  1991       Impact factor: 9.546

Review 2.  The efficacy of diuretics in acute and chronic renal failure. Focus on torasemide.

Authors:  T Risler; B Krämer; G A Müller
Journal:  Drugs       Date:  1991       Impact factor: 9.546

Review 3.  Torasemide. A review of its pharmacological properties and therapeutic potential.

Authors:  H A Friedel; M M Buckley
Journal:  Drugs       Date:  1991-01       Impact factor: 9.546

Review 4.  Benefits and risks of torasemide in congestive heart failure and essential hypertension.

Authors:  D C Brater
Journal:  Drug Saf       Date:  1996-02       Impact factor: 5.606

5.  Efficacy of oral torasemide in dogs with degenerative mitral valve disease and new onset congestive heart failure: The CARPODIEM study.

Authors:  Beatrice Besche; Thomas Blondel; Emilie Guillot; Catherine Garelli-Paar; Mark A Oyama
Journal:  J Vet Intern Med       Date:  2020-08-07       Impact factor: 3.333

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.